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Sensitivity to MDM2 inhibitors is widely different among responsive TP53 wild-type cell lines 
and tumours. Understanding the determinants of MDM2 inhibitor sensitivity is pertinent for 
their optimal clinical application. Wild-type p53-inducible phosphatase-1 (WIP1) encoded by 
PPM1D, is activated, gained/amplified in a range of TP53 wild-type malignancies and is 
involved in p53 stress response homeostasis.  
We investigated cellular growth/proliferation of TP53 wild-type and matched mutant/null cell 
line pairs, differing in PPM1D genetic status, in response to Nutlin-3/RG7388 + a highly 
selective WIP1 inhibitor GSK2830371. We also assessed the effects of GSK2830371 on 
MDM2 inhibitor induced p53Ser15 phosphorylation p53-mediated global transcriptional activity 
and apoptosis.  
The investigated cell line pairs were relatively insensitive to single agent GSK2830371. 
However, a non-growth inhibitory dose of GSK2830371 markedly potentiated the response 
to MDM2 inhibitors in TP53 wild-type cell lines, most notably in those harbouring PPM1D 
activating mutations or copy number gain (up to 5.8-fold decrease in GI50). Potentiation also 
correlated with significant increase in MDM2 inhibitor induced cell death endpoints which 
were preceded by a marked increase in a WIP1 negatively regulated substrate, 
phosphorylated p53Ser15, known to increase p53 transcriptional activity. Microarray-based 
gene expression analysis showed that the combination treatment increases the subset of 
early RG7388 induced p53-transcriptional target genes.  
These findings demonstrate that potent and selective WIP1 inhibition potentiates the 
response to MDM2 inhibitors in TP53 wild-type cells, particularly those with PPM1D 
activation or gain, while highlighting the mechanistic importance of p53Ser15 and its potential 




Mutational inactivation of the p53 tumour suppressor protein, encoded by the TP53 gene, 
occurs in ≈50% of malignancies overall (1, 2). Non-genotoxic activation of p53 in the 
remaining TP53 wild-type malignancies has attracted attention as a therapeutic strategy (3-
5). In unstressed cells p53 is rapidly turned over by binding to one of its transcriptional target 
gene products, MDM2, which inhibits p53-mediated transcription, promotes p53 ubiquitin-
mediated nuclear export and its proteasomal degradation (3). Cellular stress can activate 
effector molecules (e.g. DNA-PK, ATM and ATR) which post-translationally modify MDM2 
and or p53 leading to their dissociation followed by p53-mediated reversible cell cycle arrest, 
senescence or programmed cell death (6). Proof of concept that pharmacological inhibition 
of the MDM2-p53 interaction by small molecular weight MDM2 inhibitors can be successfully 
used for non-genotoxic activation of p53 has been established in preclinical and clinical 
settings with encouraging anti-tumour activity (4, 7). Although, It is firmly established that the 
most important determinant of response to MDM2 inhibitors is wild-type TP53 genetic status 
(Supplementary figure S1A and (8)), multiple independent studies using various classes of 
MDM2 inhibitors, and drug sensitivity data generated by the Sanger Institute, have shown 
that there is a wide range of sensitivity to MDM2 inhibitors among TP53 wild-type cell lines 
(Supplementary Figure S1B (8-10)). These highlight that the determinants of sensitivity to 
MDM2 inhibitors in a TP53 wild-type background are poorly understood. The use of 
combination regimens and patient stratification strategies are therefore being investigated to 
optimise tumour specific response in TP53 wild-type malignancies (11-13).  
Another strategy for non-genotoxic activation of p53 currently in pre-clinical development is 
inhibition of Wild-type p53-inducible phosphatase-1 (WIP1/PPM1D) which is involved in 
homeostatic regulation of p53 function and stability following cellular stress (14-16). PPM1D 
is a bona fide oncogene which is activated, gained or amplified mostly in TP53 wild-type 
malignancies (17-19). Notably, PPM1D gain-of-function mutations (activation) and TP53 
inactivating-mutations are mutually exclusive in brainstem gliomas, consistent with the role 
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of WIP1 (PPM1D gene product) in negative regulation of p53 (18). Following cellular stress, 
p53 transcriptionally induces WIP1, which forms a negative auto-modulatory loop with the 
p53 network by dephosphorylating p53 and other signalling components involved in p53 
post-translational regulation (15). In spite of selectivity and bioavailability challenges 
associated with pharmacological targeting of phosphatases (20), recently a highly selective 
allosteric WIP1 inhibitor, GSK2830371, which targets the unique flap-subdomain on WIP1 
was identified and characterised (16). Although, the response to GSK2830371 was 
contingent on wild-type TP53, some TP53 wild-type cell lines did not respond in the dose 
range associated with on-target activity (16). In a subsequent publication which highlighted 
WIP1 as a potential target in neuroblastoma, GSK2830371 was shown to effectively inhibit 
the growth of TP53 wild-type cell lines with PPM1D copy number gain. However, there was 
greater than 52-fold range in sensitivity, with NGP cells (PPM1D copy number gain) showing 
no response at all within the dose range tested (10µM cut-off) (21).  
MDM2 blocks the p53 transactivation domain by interacting with three key p53 amino acids 
(Phe19, Try23 and Leu26) which are proximal to a WIP1 substrate, phosphorylated p53Ser15 
(pp53Ser15) (22, 23). Unlike the strong influence of p53Ser20 phosphorylation on binding to 
MDM2, the phosphorylation of p53Ser15 has been reported to either have no or a modest 
effect on binding of p53 to MDM2 (24, 25), it has nevertheless been shown to contribute to 
increased p53 pro-apoptotic transcriptional transactivation activity (25-27). After MDM2 
inhibitor mediated dissociation of p53 from MDM2, phosphorylated-p53Ser15 (pp53Ser15) 
results due to basal unstimulated activity of effector kinases which normally phosphorylate 
p53Ser15 following genotoxic stress (26). This suggests that a dynamic equilibrium exists 
between kinases and phosphatases in regulating pp53Ser15 following MDM2 inhibitor induced 
p53 stabilisation, which can be tilted in favour of the p53 activating kinases by inhibiting 
WIP1. Therefore in this study we have investigated whether a selective WIP1 inhibitor 
GSK2830371 can potentiate the response to MDM2 inhibitors Nutlin-3 and RG7388 in a 
panel of cell line pairs differing in their TP53 and PPM1D genetic status. Our findings show 
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that a non-growth inhibitory dose of GSK2830371 can substantially increase sensitivity to 
MDM2 inhibitors in TP53 wild-type cell lines, particularly in those with PPM1D copy number 
gain or gain-of-function mutation.  Furthermore, global gene expression analysis showed 
that RG7388 in the presence of GSK2830371 induces additional early p53 transcriptional 
target genes involved in apoptosis in TP53 wild-type cell lines which are not responsive to 
the WIP1 inhibitor alone. We propose that the combination of WIP1 and MDM2 inhibitors can 
selectively accentuate the sensitivity to MDM2 inhibitors in TP53 wild-type tumours with 
increased WIP1 expression or activity, with elevated pp53Ser15 as a potential mechanistic 
biomarker for response to this combination. 
Materials and methods 
Cell lines and growth conditions 
All cell lines used were obtained from Northern Institute for Cancer Research cell line bank 
which only includes cell lines that have been authenticated using short tandem repeat (STR) 
DNA profiling (LGC Standards, Teddington, Middx, UK). Post-authentication passages were 
limited to 30 for experimental procedures (<6 Months) before replacing with lower passage 
number stocks. Cell line pairs used and their TP53 and PPM1D genetic status are described 
in Table 1. MCF-7 cells were used as a positive control for WIP1 protein expression and 
response to the WIP1 inhibitor GSK2830371. The S_N40R2 (SN40R2) and N_N20R1 
(N20R1) cell lines were TP53 mutant, otherwise isogenic, Nutlin-3 resistant clones derived 
from SJSA-1 and NGP cells respectively and have been cited in pre-clinical studies of 
MDM2 inhibitors (28) (See Table 1 for mutation details). U2OS-DN cells overexpress the 
R175H variant of p53 which is reported to have a dominant negative effect (29). 
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Growth inhibition assay 
Cells were seeded in 96-well plates 24 hours before treatment. Cells were then fixed with 
Carnoy's fixative and Sulphorhodamine B assay was carried out as described in (30). A 
spectrophotometer (Biorad Model 680) was used for densitometry at 570nm.  
Immunoblotting 
Western blotting was carried out as described in (31). Antibodies used were MDM2 (Ab-1) 
1:300 (#: OP46-100UG, Merck Millipore), MDMX (#: A300287A-2 Bethyl laboratories), WIP1 
(F-10) 1:200 (#: sc-376257, Santa Cruz Biotechnology), p53 1:500 (#: NCL-L-p53-DO7, 
Leica Microsystems Ltd.), phospho-p53Ser-15 1:1000 (#: 9284 Cell Signalling), p21WAF1 1:100 
(#: OP64, Calbiochem), BAX 1:1000 (#: 2772S, Cell Signalling),  cleaved caspase-3 1:1000 
(#: 9664S, New England Biolabs Ltd.), actin 1:3000 (#: A4700, Sigma-Aldrich). Secondary 
goat anti-mouse/rabbit HRP-conjugated antibodies (#: P0447/P0448, Dako) were used at 
1:1000. All antibodies were diluted in 5% milk/1 × TBS-tween (w/v). Proteins were visualised 
using enhanced chemiluminescence (GE Life Sciences) and X-ray film (Fujifilm). 
Densitometry was carried out using ImageJ software. 
Denaturing immunoprecipitation 
Treated cells were lysed (50mM Tris, 150mM NaCl, 0.2mM Na3VO4, 1% NP40 v/v, 1mM 
PMSF, Roche cOmplete protease inhibitor tablet, 1mM DTT, 2% SDS) then aliquots were 
conserved as input. Non-denaturing (No SDS) lysis buffer was used to dilute the remainder 
of the lysates (<0.1% SDS). 1-2µg of rabbit anti-ubiquitin antibody (#: FL-76, Santa Cruz) or 
rabbit IgG control (#: X0903, Dako) was added to each appropriate vessel and incubated 
overnight at 4°C. Sepharose beads (#: 17-0618-01, GE Healthcare) were then added and 
incubated for a further 4Hrs at 4°C. Beads were washed first with 0.5M KCl then with 0.1M 




2 × 104 cells/well (≈60-70% confluence) were seeded in white 96-well plates (CELLSTAR®, 
Greiner Bio-One international) and treated after 24 hours. Caspase-3/7 enzymatic activities 
were quantified by adding a 1:1 ratio of CaspaseGlo® 3/7 reagent (Promega) to growth 
media 30 min before measuring the luminescence signal using a FLUOstar Omega plate 
reader (BMG Labtech) and all values were expressed as a ratio of signal relative to solvent 
control.  
Expression array 
NGP cells were seeded at 6 x 105 cells per well of a 6-well plate and treated with either 
DMSO or 75nM of RG7388 (≈GI50) ± 2.5μM GSK2830371 for 4 hours before RNA 
extraction using RNeasy Plus Mini Kit (Qiagen). Concentration and quality of mRNA were 
determined using  Agilent RNA 6000 nano kit on an Agilent 2100 Bioanalyzer (RNA integrity 
numbers > 9) AROS applied biotechnology for gene expression analysis using Illumina 
Beadchip expression arrays (HumanHT-12 v4.0). Array data processing, background 
correction, normalisation and quality control checks were performed using the R package 
‘Lumi’ (bioconductor.org). Probe intensity values were converted to VSD (variance stabilized 
data). Robust spline normalization (RSN) was used as an array normalization method. Poor 
quality probes (detection threshold < 0.01), and probes that are not detected at all in the 
remaining arrays were removed prior to downstream analysis. The remaining probe 
normalized intensity values (18,634) were used in the differential expression analysis. The 
data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus 




RNA extraction and Quantitative real-time polymerase chain reaction (qRT-
PCR) 
Complementary DNA was generated using the Promega Reverse Transcription System 
(A3500, Promega) as described by the manufacturer. qRT-PCR was carried out using 
SYBR® green RT-PCR master mix (Life technologies) as per the manufacturer’s guidelines 
and the following primers (5’-3’): CDKN1A (Forward (F)-TGTCCGTCAGAACCCATGC, 
Reverse (R)-AAAGTCGAAGTTCCATCGCTC), TP53INP1 (F-
TCTTGAGTGCTTGGCTGATACA, R-GGTGGGGTGATAAACCAGCTC), BTG2 (F-
CCTGTGGGTGGACCCCTAT, R-GGCCTCCTCGTACAAGACG), MDM2 (F-
CAGTAGCAGTGAATCTACAGGGA, R- CTGATCCAACCAATCACCTGAAT) and GAPDH 
(F-CAATGACCCCTTCATTGACC, R-GATCTCGCTCCTGGAAGAT). 50ng/µl of the cDNA 
samples per 10µl final reaction volume, with the standard cycling parameters (Stage 1: 50˚C 
for 2min, Stage 2: 95˚C for 10min then 40 cycles of 95˚C for 15 Sec and 60˚C for 1 min), 
were set and carried out on an ABI 7900HT sequence detection system. Data were 
presented as mean ± standard error of mean (SEM) relative quantities (RQ) of four 
independent repeats where GAPDH was used as endogenous control and DMSO used as 
the calibrator for each independent repeat with the formula 2-ΔΔCT. Analysis was carried out 
using SDS 2.2 software (Applied Biosystems).  
Site-directed mutagenesis and p53 overexpression 
Plasmid vector used in this study, pcDNA3.1 (+/-) (Life Technologies, # V790-20 and V795-
20) and full-length human TP53 cDNA cloned into this backbone. The Gozani lab protocol 
for site directed mutagenesis (33) was used to generate the p53Ser15 mutants. Primers used: 
p53S15A (F-GTCGAGCCCCCTCTGGCTCAGGAAACATTTTCA, R- 
TGAAAATGTTTCCTGAGCCAGAGGGGGCTCGAC) and p53S15D (F- 
GTCGAGCCCCCTCTGGACCAGGAAACATTTTCA, R-
TGAAAATGTTTCCTGGTCCAGAGGGGGCTCGAC). HCT116-/- cells were transfected with 
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Lipofectamine 2000 and plasmid DNA 12 hours before lysates were collected at different 
time intervals. 
Flow Cytometry 
After treatment, floating and adhered cells were pooled and incubated in propidium iodide 
solution (150μM propidium iodide (Calbiochem, San Diego, CA), 1.46μM DNase free-RNase 
A (Sigma, St. Louis, MO), 3.88mM sodium citrate (Sigma, St. Louis, MO) and 0.3% Triton-X 
100 (Sigma, St. Louis, MO)) for 10 min at 25ºC and then fluourescence-activated cell sorting 
(FACS) was carried out using a FACSCalibur™ (BD Biosciences). CellQuest software was 
used to establish cell cycle distribution and gated histograms.  
Statistical analysis 
Statistical tests were carried out in GraphPad Prism 6 software and all p-values represent 
two-tailed paired t-tests of 3 or more independent repeats unless otherwise stated. For 
microarray differential expression analysis R-statistical software was used. Microarray data 
was processed using R Bioconductor package lumi (34) Probes intensity values were 
transformed using variance stabilising transformation implemented in the lumi package 
before data normalisation. The robust spline normalization was used as a normalization 
method. Poor quality probes (detection threshold < 0.01), and probes that are not detected 
at all in the remaining arrays were removed. Differential expression analysis was performed 
using R Bioconductor package limma (35).   
Results 
GSK2830371 potentiates the response to MDM2 inhibitors Nutlin-3 and RG7388 
in a p53-dependent manner 
Growth inhibition assays were carried out on a panel of TP53 wild-type and mutant/null cell 
line pairs differing in their PPM1D genetic status, to assess their sensitivity to the selective 
allosteric WIP1 inhibitor GSK2830371 and its ability in turn to sensitise cells to MDM2 
10 
 
inhibitors (Figure 1A).  GSK2830371 sensitive MCF-7 cells were used as a positive control 
for the growth inhibitory activity and biochemical effect of this compound. GSK2830371 had 
a 50% growth inhibitory concentration (GI50) of 2.65µM + 0.54 (SEM) in MCF-7 cells. The 
growth inhibition curve for GSK2830371 plateaued in MCF-7 cells at doses 2.5µM-10µM 
suggesting that a subpopulation of MCF-7 cells are resistant to growth inhibition and 
apoptosis in response to maximal WIP1 inhibition (Figure 1A). All other cell line pairs were 
not sensitive to growth inhibition by GSK2830371 alone, with GI50 > 10µM irrespective of 
their PPM1D or TP53 genetic status (Figure 1A). Basal expression of WIP1 across the panel 
of cell line pairs was assessed by immunoblotting with an antibody that detects WIP1 (FL-
WIP1), its previously described shorter isoform (S-WIP1) (36), and the two WIP1 gain-of-
function mutant proteins in HCT116 and U2OS cell line pairs (Figure 1B). Transient 
knockdown of WIP1 using four different anti-PPM1D siRNA constructs resulted in a 
reduction in the intensity of all the bands detected by the WIP1 antibody (F-10) which 
suggests that all of the bands detected in these conditions correspond to WIP1 
(Supplementary figure S2A). This includes a further WIP1 isoform detected by F-10 
(≈55kDa), which is referred to here as S*-WIP1. PPM1D-amplified MCF-7 cells (37) showed 
the highest basal expression of WIP1 and its isoforms, consistent with their sensitivity to 
GSK2830371 single treatment (Figure 1B) (See (38)). NGP cells, with PPM1D copy number 
gain (21), and its otherwise isogenic TP53 mutant daughter cell line, N20R1, were 
insensitive to <10µM GSK2830371 despite showing the second highest expression of full-
length WIP1 after MCF-7 cells. The SJSA-1 and SN40R2 TP53 wild-type and mutant pair, 
with wild-type PPM1D, showed the least WIP1 protein expression among all cell line pairs in 
the panel. Shorter bands corresponding to the previously reported truncated and activating 
WIP1 mutant proteins WIP1 L450X and WIP1 R458X were detected in lysates derived from 
HCT116 and U2OS cell line pairs respectively (Figure 1B) (39).  
Due to the role of WIP1 in homeostatic feedback regulation of the p53 network we aimed to 
assess whether GSK2830371 (WIP1i) can potentiate the response to MDM2 inhibitors. 
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Treatment with a combination of the highest non-growth inhibitory dose of GSK2830371 
(2.5µM), potentiated the response to MDM2 inhibitors Nutlin-3 and RG7388 in a p53-
dependent manner in cell lines that were not sensitive to growth inhibition by GSK2830371 
alone (Figure 1C). TP53 wild-type parental cell lines HCT116+/+, NGP and SJSA-1 showed a 
2.4-fold (p=0.007), 2.1-fold (p=0.039) and 1.3-fold (p =0.017) decrease respectively in their 
Nutlin-3 GI50 values in the presence of 2.5μM GSK2830371. In contrast Nutlin-3 GI50 did 
not change for theirTP53 Null/Mutant matched pairs HCT116-/-, N20R1 and SN40R2. 
However, pertinent to the widening of RG7388 therapeutic index in the clinic, the same dose 
of GSK2830371 resulted in a much greater potentiation of RG7388 in TP53 wild-type cell 
lines with either PPM1D gain-of-function or copy number gain: NGP 5.8-fold (p=0.049), and 
HCT116+/+ 4.8-fold (p=0.018) compared to PPM1D wild-type SJSA-1 cells 1.4-fold (p=0.020) 
(Figure 1C). U2OS TP53 wild-type cells showed a similar trend towards potentiation of 
Nutlin-3 in combination with GSK2830371 at 1.25µM as Nutlin-3 GI50 was reduced by 3.2-
fold (p=0.08), however the same dose of the WIP1 inhibitor resulted in a 5.3-fold (p=0.039) 
decrease in RG7388 GI50. None of the TP53 mutant daughter cell lines showed increased 
sensitivity to RG7388 in the presence of the WIP1 inhibitor. Interestingly, the combination of 
Nutlin-3 or RG7388 with 2.5µM GSK2830371 also augmented the growth inhibitory effect in 
MCF-7 cells compared to each drug alone. Therefore, the most marked fold-change in 
sensitivity to both MDM2 inhibitors was observed in TP53 wild-type cell lines that have 
increased WIP1 expression or activity.  
Inhibition of WIP1 catalytic activity by GSK2830371 is separable from its 
induction of ubiquitin-mediated WIP1 degradation 
Treatment of MCF-7 cells with 2.5µM GSK2830371 resulted in marked time-dependent 
degradation of both isoforms of WIP1 over 8 hours which correlated with p53 stabilisation 
and phospho-p53Ser15 (pp53Ser15) consistent with previous reports by Gilmartin et al., (Figure 
2A) (16). Quantification of WIP1 signal intensity is presented in Supplementary figure S2B.  
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To test the effect of the GSK2830371 inhibitor on WIP1 phosphatase activity separate from 
degradation of WIP1, its effect on the phosphorylation of p53Ser15 30 min following exposure 
of MCF7 cells to ionising radiation was used. GSK2830371 was seen to inhibit pp53Ser15 
dephosphorylation at a time point when the WIP1 protein expression had not yet been 
affected by this compound (Compare pp53Ser15 on the last two tracks in Figure 2B). These 
data show that inhibition of the catalytic activity of WIP1 by GSK2830371 is separable from 
its ubiquitin-mediated degradation.   
It was noteworthy that GSK2830371 also lead to the degradation of truncated WIP1 mutants 
within 4 hours (Figure 2C). We carried out a denaturing immunoprecipitation (IP) experiment 
probing for all ubiquitinated species in HCT116+/+ cells treated with the proteasome inhibitor 
MG132 and either GSK2830371 alone or in combination with Nutlin-3, to assess whether 
wild-type WIP1 and WIP1 L450X are both degraded by ubiquitin mediated processes (Figure 
2C). The anti-ubiquitin antibody (Ub-Ab) migrated to a similar molecular weight as full-length 
WIP1 and it was detected by the goat anti mouse antibody (Figure 2D, last lane Ub-Ab 
Control); therefore, the ubiquitination of full-length WIP1 could not be determined. However, 
ubiquitinated WIP1 L450X was observed to be increased by GSK2830371 (Figure 2D). 
Interestingly this ubiquitination event was also reduced in the presence of Nutlin-3. 
Increased ubiquitination of p53 in the presence of MG132 + GSK2830371 was reversed by 
Nutlin-3 as expected because inhibiting MDM2-p53 interaction prevents MDM2 mediated 
p53-ubiquitination.  
GSK2830371 significantly increases MDM2 inhibitor mediated apoptosis and 
reduces clonogenic cell survival in TP53 wild-type cell lines  
The combination of GSK2830371 and multiples of Nutlin-3 GI50 dose resulted in a marked 
increase in caspase-3/7 activity in both NGP and SJSA-1 cells compared to treatment with 
either drug alone (Figure 3A & 3B). For NGP cells, 24 hour treatment with 2.5µM 
GSK2830371 did not lead to detectable caspase-3/7 activity, whereas Nutlin-3 at 0.5 × and 1 
× GI50 resulted in a dose-dependent increase in caspase 3/7 signal which was significantly 
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enhanced  (≈4-fold p=0.005 and ≈3-fold p=0.02 respectively) in the presence of 2.5µM 
GSK2830371 (Figure 3A). No increased caspase-3/7 activity was observed in SJSA-1 cells 
after 24 hours of exposure to 2.5µM GSK2830371 alone or Nutlin-3 + 2.5µM GSK2830371 
(data not shown). Similarly in both cell line pairs, 48 hours treatment with 2.5µM 
GSK2830371 alone resulted in no increased caspase-3/7 activity, whereas its presence 
significantly increased response to Nutlin-3  (≈2.7-fold p=0.01 in NGP, ≈2- fold p=0.04 in 
SJSA-1) in a p53-dependent manner (Figure 3B). 
Caspase-3/7 activity could not be detected in HCT116+/+ and for up to 48 hours following 
treatment (data not shown), so continuous exposure cloning efficiency experiments were 
carried out as described in Figure 3C (see caption) in order to assess clonogenic cell 
survival. There was no reduction in clonogenic efficiency in the presence of the 
GSK2830371 alone in comparison with untreated controls. Cloning efficiency of HCT116+/+ 
cells in the presence of 0.5 × Nutlin-3 GI50 significantly decreased (p=0.008) when 
GSK2830371 was present at 2.5µM (Figure 3C). 
In NGP cells pp53Ser15 was not affected by the GI50 dose of Nutlin-3 or 2.5µM GSK2830371 
alone, whereas in combination there was a marked increase in pp53Ser15 at 4 hours which 
persisted through to 24 hours  and correlated with the detection of cleaved caspase-3 
(Figure 3D & 3E). GSK2830371 alone resulted in modest p53 stabilisation in NGP cells, after 
24 hours treatment, which did not result in detectable induction of p53 direct transcriptional 
targets p21WAF1 and MDM2 (Figure 3E). Interestingly, monotreatment with the same dose of 
GSK2830371 in MCF-7 cells was sufficient for WIP1 degradation, p53 stabilisation and 
increase pp53Ser15 in contrast to NGP cells (Figure 2A v Figure 3E). Consistently, WIP1 was 
also degraded in NGP cells in the presence of the WIP1 inhibitor (track 3 v’s track 1 in 
Figure 3D) even when WIP1 was induced by Nutlin-3 (track 4 v’s track 2 in Figure 3D). The 
lack of a p53 response of NGP cells to 2.5µM GSK2830371 may explain their insensitivtiy to 
GSK2830371 monotreatment compared to MCF-7 cells. Also the addition of 2.5µM 
GSK283037 did not affect MDM2 induction by Nutlin-3 (Figure 3D). This suggests that the 
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reported role of WIP1 in downregulation of MDM2 (14) may be counterbalanced by the p53-
dependent transcriptional induction of MDM2 in the presence of Nutlin-3. There was a 
reduction in MDMX expression 24 hours after combination treatment compared to Nutlin-3 
treatment alone (Figure 3D). Given that MDMX increased expression has been proposed to 
contribute to reduced sensitivity to MDM2 inhibitors (40) it is likely that the role of WIP1 in 
negative regulation of MDMX stability (41) may be a factor in its ability to potentiate MDM2 
inhibitors in MDMX overexpressing NGP cells. There was no change the expression of the 
p53 proapoptotic transcriptional target BAX at 4 and 24 hours following combination 
treatment compared to Nutlin-3 or WIP1 inhibitor monotreatments (Figure 3D). This suggests 
that BAX is likely not involved in potentiation of Nutlin-3 by the WIP1 inhibitors. 
GSK2830371 increases RG7388 induced p53-dependent transcription of 
growth inhibitory and pro-apoptotic genes 
Phosphorylation of p53Ser15 has been reported to increase p53-mediated transcriptional 
transactivation but not to be necessary for dissociation of p53 from MDM2 in response to 
DNA damage (24, 26). Also reports in the literature have suggested that p53 post-
translational modifications can behave as variable barcodes and induce transcription of 
alternate sets of p53 target genes which could lead to different cell fates after p53 activation 
(42). As the greatest potentiation of MDM2 inhibitors by GSK2830371 was observed in NGP 
cells (5.8-fold), we assessed whether the subset of early genes activated in response to 
RG7388 in this cell line differed in the presence of 2.5µM GSK2830371 which produced a 
marked increase in pp53Ser15. Peak p53 transcriptional target expression (e.g. p21WAF1 and 
MDM2) as detected by western blotting is reached by 6-8 hours after treatment (Figure 3E). 
Because later changes in transcription may be secondary effects and not directly p53-
dependent, we assessed changes in global gene expression 4 hours following RG7388 
(GI50 ≈ 75nM) ± 2.5µM GSK2830371 using the Illumina BeadChip expression array 
platform. A testament to the specificity of RG7388 in exclusively activating p53, 4 hours of 
exposure to a GI50 dose of RG7388 led to significantly increased mRNA expression of only 
15 
 
9 genes, all which were known p53 transcriptional targets (Figure 4A). The top 41 genes just 
below the statistical significance cut-off point (p>0.05 after correction for multiple testing) 
were also mostly genes that are well-established to be direct p53 transcriptional targets. 
Interestingly, in the presence of 2.5µM GSK2830371 the subset of statistically significant 
RG7388 mediated transcriptional changes increased from 9 to 24 genes, indicating that 
inhibition of WIP1 results in a significant increase of additional p53-mediated transcriptional 
activity at this early time point (Figure 4B) (For a list of genes refer to Supplementary table 
S1A and Supplementary table S1B).  
To validate the results of the array we assessed the expression of the top three genes with 
the highest odds ratio difference between single and combination treatments (CDKN1A 
(p21WAF1), TP53INP1, and BTG2) and one of the genes that was exclusively induced in the 
combination treatment (MDM2) by qRT-PCR using the same mRNA samples used in the 
expression array experiment (Figure 4C). Consistent with the array data, all the genes tested 
showed significant increase in their mRNA expression in combination treatment compared to 
the RG7388 alone (Figure 4C). TP53INP1/P53DINP1 is a known pro-apoptotic p53 
transcriptional target gene, the overexpression or induction of which following cellular stress 
has been associated with increased p53-mediated apoptosis (43). Among the 16 additional 
p53 regulated target genes induced exclusively in response to the combination treatment 
were tumour necrosis factor super family member 10B (TNFRSF10B) and p53-induced 
death domain protein 1 (PIDD1), two genes critical for extrinsic and intrinsic pro-apoptotic 
pathways respectively (44-47). Interestingly,  despite neither of the agents being genotoxic, 
one of the other genes that showed differential expression in response to the combination 
treatment was the DNA base excision repair gene xeroderma pigmentosum 
complementation group C (XPC), the increased basal expression of which has been 
reported to correlate with increased sensitivity to MDM2 inhibitors in a large panel of TP53 
wild-type cell lines and predict a better clinical response to RG7112 and RG7388 in acute 
myeloid leukaemia patients (13). 
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The increase in the subset of genes expressed correlated with a marked increase in the 
proportion of pp53Ser15 to total p53 in immunoblots of lysates prepared in parallel to the 
mRNA samples used in the expression array experiment (Figure 4D & see Supplementary 
figure S3A). These data suggest that the underlying mechanism for the observed 
potentiation of MDM2 inhibitors in combination with WIP1 phosphatase inhibition may be 
contributed to by the increased p53Ser15 phosphorylation which enhances p53-dependent 
pro-apoptotic gene transcription. 
In line with this hypothesis, increased pp53Ser15 phosphorylation in HCT116+/+ following 
combination treatment resulted an in increase in the p21WAF1 product of the CDKN1A gene in 
comparison to monotreatment with either drug (Figure 4E). In order to confirm earlier 
findings showing that phosphorylation of p53Ser15 increases p53-mediated transcription in 
HCT116 cells, we overexpressed wild-type (Wt) p53, mutant p53S15A or p53S15D in HCT116-/- 
cells and assessed p53-mediated expression of p21WAF1 protein encoded by the CDKN1A 
gene, which had showed the biggest fold-change in expression on the array following the 
combination treatment in NGP cells. Consistent with previous findings (24, 26) Wt p53 and 
phospho-mimetic p53S15D mutant constructs increased p53-mediated expression of p21WAF1 
and MDM2 following transfection compared to the p53S15A mutant which could not be 
phosphorylated on that residue (Figure 4F). See Supplementary figure S3B & S3C for repeat 
and densitometry data. 
The effect of combined MDM2 and WIP1 inhibition on cell cycle distribution 
Given that WIP1 inhibition potentiated the growth inhibitory and apoptotic response of TP53 
wild-type cell lines to MDM2 inhibitors, and the highest fold increase in transcription was of 
the CDKN1A (p21WAF1) cyclin-dependent kinase inhibitor gene, we investigated changes in 
cell cycle distribution following this combination treatment. In all cell lines, 2.5µM 
GSK2830371 alone did not significantly affect cell cycle distribution throughout 72 hours of 
treatment (Figure 5A & Supplementary figure S4). Changes in cell cycle distribution after 
exposure to Nutlin-3 + 2.5µM GSK2830371 were cell line-dependent. In SJSA-1 and NGP 
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cell lines, 24 hours exposure to Nutlin-3 resulted in an increase in the proportion of cells in 
G1/G0 phases of the cell cycle. In SJSA-1 cells this effect of Nutlin-3 remained unchanged in 
the following 48 hours treatment with Nutlin-3 + GSK2830371. However, in NGP cells the 
relative proportion of cells in G2/M and S-phase increased over the following 48 hours when 
Nutlin-3 and the WIP1 inhibitor were combined compared to Nutlin-3 alone. In HCT116+/+ 
cells Nutlin-3 resulted in an increase in the proportion of cells in G0/G1 and G2/M phases at 
24 hours, which persisted to the 72 hours treatment time point (Figure 5A), consistent with 
the increase in CDKN1A (p21WAF1) expression in response to the combination treatment 
(Figure 4E). Cell cycle distribution was not affected in HCT116-/- cells regardless of the 
treatment condition, suggesting that the changes in cell cycle distribution observed in 
HCT116+/+ cells are p53-dependent (Figure 5A).  
Sub-G1 changes 
In response to the combination treatment compared to Nutlin-3 alone, the increase in Sub-
G1 FACS signal after exposure to Nutlin-3 was significantly augmented in the presence of 
2.5µM GSK2830371 (WIP1i) in both SJSA-1 and NGP cell lines (Figure 5B and 
Supplementary figure S4B). This is in keeping with the increased cleaved caspase-3/7 
activity in NGP and SJSA-1 cells (Figure 3A & 3B). Sub-G1 signals were not significantly 
changed in HCT116+/+cells throughout the 72 hours of Nutlin-3 ± GSK2830371 treatment 
(Figure 5B).  
Discussion  
Although mutant TP53 status is a dominant mechanism of resistance to MDM2-p53 there is 
nevertheless a clinically relevant wide range of sensitivity to MDM2 inhibitors among TP53 
wild-type cancer cell lines. Importantly, this variation of response is not exclusive to one 
class of MDM2 inhibitors and is clearly seen in panels of cell lines with validated wild-type 
TP53 status. Amgen have recently reported a wide range of sensitivity to their MDM2 
inhibitor AMGMDS3 among their carefully curated panel of TP53 wild-type and functional cell 
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lines showing a 500-fold GI50 difference between the least to most sensitive (8). These 
observations suggest that there are a diverse set of underlying genetic variables that 
determine cell fate following a dose of activated/stabilised p53. Here we have shown a non-
growth inhibitory dose of the selective orally bioavailable allosteric WIP1 phosphatase 
inhibitor, GSK2830371, can modulate the phosphorylation state of p53 and potentiate both 
the growth inhibitory and apoptotic response to MDM2 inhibitors in TP53 wild-type cell lines, 
especially those with increased WIP1 expression or activity. MDM2 inhibitor potentiation was 
at its greatest when the cell line harboured either PPM1D copy number gain/elevated 
expression or gain-of-function truncating mutations, thus providing a rationale for specific 
combination treatment targeting of tumours with this genotype.  
The argument in support of p53Ser15 phosphorylation increasing p53-mediated transcription 
(24, 26, 27) is compelling and consistent with our findings. In contrast to what was originally 
reported by Vassilev et al., in 2004, phosphorylation of p53 following treatment with MDM2 
inhibitors is observed, however it is not as intense and immediate compared to p53Ser15 
phosphorylation following DNA damaging agents of equivalent growth inhibitory dose (7, 26). 
As shown by Loughery et al., the basal activity of kinases involved in phosphorylation of 
p53Ser15 (e.g. ATM and ATR) in response to DNA damage are also likely responsible for, or 
contribute to, this post-translational modification in response to MDM2 inhibitors (26). Our 
findings have shown that, in the presence of a selective WIP1 inhibitor, the minimal 
phosphorylation of p53Ser15 in response to MDM2 inhibitors is markedly accentuated, which 
correlates with potentiation of apoptotic and growth inhibitory response to MDM2 inhibitors in 
TP53 wild-type cells, particularly in those with high WIP1 expression or activity. This was 
also associated with significantly increased transcript levels from an increased number of 
immediate p53 transcriptional target genes as compared to those induced by single agent 
RG7388. Increased p53Ser15 phosphorylation in response to the combination treatment also 
resulted in increased p21WAF1 and MDM2 protein expression. Consistent with the reported 
role of p53Ser15 phosphorylation in increasing transcriptional activity of p53 we also confirmed 
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that mutation of this residue influenced expression of p21WAF1 and MDM2 proteins. Thus our 
current working model includes evidence for the role of enhanced p53 transcriptional activity 
in response to the combination of MDM2 inhibitors and GSK2830371 (Figure 6). It is likely 
however, that direct and or indirect WIP1 mediated post-translational modifications that 
effect the stability and function of stress response proteins and their cross-talk with the p53 
network (As reviewed in (15)) may also contribute to MDM2 inhibitor potentiation in the 
presence of GSK2830371. Regardless of this, our data strongly suggest that increased 
phosphorylated p53Ser15 can be considered a surrogate marker of p53 dissociation from 
MDM2 in response to single agent GSK2830371 treatment or its combination with MDM2 
inhibitors, since this modification coincides with p53 transcriptional activation that precedes 
the subsequent enhanced p53-mediated growth inhibitory or apoptotic response to each of 
these treatments. 
Nutlin-3 mediated changes in cell cycle distribution were all enhanced in the presence of a 
dose of GSK2830371 which on its own did not affect cell cycle distribution. The observed 
increase in Sub-G1 FACS analysis signals with combination treatment of NGP cells is 
consistent with potentiation of apoptosis and growth inhibition in this cell line. Enhancement 
of Nutlin-3 mediated G1:S and G2:S ratios in the presence of GSK2830371 are also 
consistent with the increased CDKN1A (p21WAF1) expression observed at both transcript and 
protein levels and its importance in negative regulation of cell cycle progression (48, 49). 
Kleiblova et al., (39) had previously shown that transient knockdown of truncated PPM1D 
increases G1 checkpoint in response to ionising radiation (IR). Interestingly, in our current 
study WIP1 inhibition and depletion by GSK2830371 in HCT116+/+ cells harbouring a 
PPM1D L450X truncation mutation also resulted in an increase in p53-dependent G1 arrest 
following p53 activation by Nutlin-3, while this did not occur in NGP and SJSA-1 cell lines 
that do not have PPM1D gain of function mutations. Lindqvist A. et al., 2009 (50) also 
reported that WIP1 knockdown ablates the competence of cellular p53-dependent G2 
checkpoint recovery following cellular stress, although the authors were not aware of the 
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gain of function WIP1 R458X mutation in U2OS cells used in their study, as it had not yet 
been reported. These findings suggest that the increase in G2:S ratio observed in HCT116+/+ 
cells treated with the combination of MDM2 inhibitors and GSK2830371 is likely due to 
inhibition of WIP1 L450X which would otherwise be negatively regulating p53 transcriptional 
activity in these cell lines. Of note we have also shown that GSK2830371 increases the 
ubiquitin mediated degradation of truncated WIP1 as postulated by Gilmartin et al., (16). 
Interestingly, this increase in the ubiquitination of truncated WIP1 was reversed by inhibition 
of MDM2 which suggests that MDM2 is directly or indirectly involved in WIP1 ubiquitination 
following GSK2830371.  
Wild-type TP53 genetic status is the most important determinant of response to MDM2 
inhibitors, while being necessary but not sufficient for growth inhibitory response to WIP1 
inhibition by GSK2830371. Following their promising clinical outcomes so far, MDM2 
inhibitors will be explored in combination with other anticancer agents to optimise their 
therapeutic potential. Combination regimens of these non-genotoxic agents could minimise 
DNA damage to healthy tissue which does not express altered forms of PPM1D. Here we 
have shown that specific pharmacological inhibition of WIP1 combined with MDM2 inhibitors 
is a promising therapeutic strategy in TP53 wild-type tumours that show increased WIP1 
function, and that phosphorylated p53Ser15  and PPM1D genotype are important both 
mechanistically and as  predictive biomarkers for response to this combination treatment. 
Acknowledgements:  
I would like to thank Professor Nicola J Curtin’s contribution for providing the U2OS cell line 
pair. I would also like to acknowledge Mrs Mahsa Azizyan, Drs Olivier Binda and Richard 
Heath for their provision of reagents and advice on experimental procedures. The 
encouragement and provision of RG7388 by Professor Newell and the NICR Drug Discovery 




1. Levine AJ, Momand J, Finlay CA. THE P53 TUMOR SUPPRESSOR GENE. Nature. 1991;351:453-
6. 
2. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323-31. 
3. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the 
p53 pathway. Nat Rev Cancer. 2009;9:862-73. 
4. Zhao Y, Aguilar A, Bernard D, Wang S. Small-Molecule Inhibitors of the MDM2–p53 Protein–
Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment. Journal of Medicinal 
Chemistry. 2015;58:1038-52. 
5. Li Q, Lozano G. Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy. Clinical 
cancer research : an official journal of the American Association for Cancer Research. 2013;19:34-41. 
6. Meek DW, Hupp TR. The regulation of MDM2 by multisite phosphorylation—Opportunities 
for molecular-based intervention to target tumours? Seminars in Cancer Biology. 2010;20:19-28. 
7. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the 
p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303:844-8. 
8. Saiki AY, Caenepeel S, Cosgrove E, Su C, Boedigheimer M, Oliner JD. Identifying the 
determinants of response to MDM2 inhibition. Oncotarget. 2015;6:7701-12. 
9. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, et al. Systematic 
identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012;483:570-5. 
10. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer 
Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 
2012;483:603-307. 
11. Jin Z, Shen J, He J, Hu C. Combination therapy with p53–MDM2 binding inhibitors for 
malignancies. Med Chem Res. 2015;24:1369-79. 
12. Sullivan KD, Padilla-Just N, Henry RE, Porter CC, Kim J, Tentler JJ, et al. ATM and MET kinases 
are synthetic lethal with non-genotoxic activation of p53. Nature chemical biology. 2012;8:646-54. 
13. Zhong H, Chen G, Jukofsky L, Geho D, Han SW, Birzele F, et al. MDM2 antagonist clinical 
response association with a gene expression signature in acute myeloid leukaemia. British Journal of 
Haematology. 2015:n/a-n/a. 
14. Lu X, Ma O, Nguyen T-A, Joness SN, Oren M, Donehower LA. The Wip1 phosphatase acts as a 
gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell. 2007;12:342-54. 
15. Lowe J, Cha H, Lee M-O, Mazur SJ, Appella E, Fornace AJ. Regulation of the Wip1 
phosphatase and its effects on the stress response. Frontiers in bioscience : a journal and virtual 
library. 2012;17:1480-98. 
16. Gilmartin AG, Faitg TH, Richter M, Groy A, Seefeld MA, Darcy MG, et al. Allosteric Wip1 
phosphatase inhibition through flap-subdomain interaction. Nat Chem Biol. 2014;10:181-7. 
17. Bulavin DV, Demidov ON, Saito S, Kauraniemi P, Phillips C, Amundson SA, et al. Amplification 
of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nature Genet. 2002;31:210-5. 
18. Zhang L, Chen LH, Wan H, Yang R, Wang Z, Feng J, et al. Exome sequencing identifies somatic 
gain-of-function PPM1D mutations in brainstem gliomas. Nat Genet. 2014;46:726-30. 
19. Ruark E, Snape K, Humburg P, Loveday C, Bajrami I, Brough R, et al. Mosaic PPM1D 
mutations are associated with predisposition to breast and ovarian cancer. Nature. 2013;493:406-
10. 
20. Vintonyak VV, Antonchick AP, Rauh D, Waldmann H. The therapeutic potential of 
phosphatase inhibitors. Current Opinion in Chemical Biology. 2009;13:272-83. 
21. Richter M, Dayaram T, Gilmartin AG, Ganji G, Pemmasani SK, Van Der Key H, et al. WIP1 
Phosphatase as a Potential Therapeutic Target in Neuroblastoma. PLoS One. 2015;10:e0115635. 
22. Böttger A, Böttger V, Garcia-Echeverria C, Chène P, Hochkeppel H-K, Sampson W, et al. 




23. Lu X, Nannenga B, Donehower LA. PPM1D dephosphorylates Chk1 and p53 and abrogates 
cell cycle checkpoints. Genes & Development. 2005;19:1162-74. 
24. Dumaz N, Meek DW. Serine15 phosphorylation stimulates p53 transactivation but does not 
directly influence interaction with HDM2. The EMBO Journal. 1999;18:7002-10. 
25. Chehab NH, Malikzay A, Stavridi ES, Halazonetis TD. Phosphorylation of Ser-20 mediates 
stabilization of human p53 in response to DNA damage. Proceedings of the National Academy of 
Sciences. 1999;96:13777-82. 
26. Loughery J, Cox M, Smith LM, Meek DW. Critical role for p53-serine 15 phosphorylation in 
stimulating transactivation at p53-responsive promoters. Nucleic Acids Research. 2014;42:7666-80. 
27. Unger T, Sionov RV, Moallem E, Yee CL, Howley PM, Oren M, et al. Mutations in serines 15 
and 20 of human p53 impair its apoptotic activity. Oncogene. 1999;18:3205-12. 
28. Chen L, Rousseau RF, Middleton SA, Nichols GL, Newell DR, Lunec J, et al. Pre-clinical 
evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in 
neuroblastoma. Oncotarget. 2015;6:10207-21. 
29. Allan LA, Fried M. p53-dependent apoptosis or growth arrest induced by different forms of 
radiation in U2OS cells: p21WAF1/CIP1 repression in UV induced apoptosis. Oncogene. 
1999;18:5403-12. 
30. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New Colorimetric 
Cytotoxicity Assay for Anticancer-Drug Screening. Journal of the National Cancer Institute. 
1990;82:1107-12. 
31. Chen L, Zhao Y, Halliday GC, Berry P, Rousseau RF, Middleton SA, et al. Structurally diverse 
MDM2-p53 antagonists act as modulators of MDR-1 function in neuroblastoma. Br J Cancer. 
2014;111:716-25. 
32. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and 
hybridization array data repository. Nucleic Acids Research. 2002;30:207-10. 
33. Gozani O. Site Directed Mutagenesis with Stratagene Pfu Turbo. Available from: 
http://web.stanford.edu/group/gozani/cgi-bin/gozanilab/wp-content/uploads/2014/01/Site-
Directed-Mutagenesis-with-Stratagene-Pfu-Turbo.pdf 
34. Du P, Kibbe WA, Lin SM. lumi: a pipeline for processing Illumina microarray. Bioinformatics 
(Oxford, England). 2008;24:1547-8. 
35. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential 
expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Research. 2015. 
36. Chuman Y, Kurihashi W, Mizukami Y, Nashimoto T, Yagi H, Sakaguchi K. PPM1D430, a Novel 
Alternative Splicing Variant of the Human PPM1D, can Dephosphorylate p53 and Exhibits Specific 
Tissue Expression. Journal of Biochemistry. 2009;145:1-12. 
37. Castellino R, De Bortoli M, Lu X, Moon S-H, Nguyen T-A, Shepard M, et al. Medulloblastomas 
overexpress the p53-inactivating oncogene WIP1/PPM1D. J Neurooncol. 2008;86:245-56. 
38. Li J, Yang Y, Peng Y, Austin RJ, van Eyndhoven WG, Nguyen KCQ, et al. Oncogenic properties 
of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat Genet. 2002;31:133-
4. 
39. Kleiblova P, Shaltiel IA, Benada J, Ševčík J, Pecháčková S, Pohlreich P, et al. Gain-of-function 
mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint. The Journal of Cell Biology. 
2013;201:511-21. 
40. Marine J-CW, Dyer MA, Jochemsen AG. MDMX: from bench to bedside. Journal of Cell 
Science. 2007;120:371-8. 
41. Zhang X, Lin L, Guo H, Yang J, Jones SN, Jochemsen A, et al. Phosphorylation and 
Degradation of MdmX is Inhibited by Wip1 Phosphatase in the DNA Damage Response. Cancer 
research. 2009;69:7960-8. 
42. Murray-Zmijewski F, Slee EA, Lu X. A complex barcode underlies the heterogeneous 
response of p53 to stress. Nat Rev Mol Cell Biol. 2008;9:702-12. 
23 
 
43. Okamura S, Arakawa H, Tanaka T, Nakanishi H, Ng CC, Taya Y, et al. p53DINP1, a p53-
Inducible Gene, Regulates p53-Dependent Apoptosis. Molecular Cell. 2001;8:85-94. 
44. Wu GS, Burns TF, McDonald ER, Jiang W, Meng R, Krantz ID, et al. KILLER/DR5 is a DNA 
damage-inducible p53-regulated death receptor gene. Nat Genet. 1997;17:141-3. 
45. Ashkenazi A, Dixit VM. Death Receptors: Signaling and Modulation. Science. 1998;281:1305-
8. 
46. Lin YP, Ma WL, Benchimol S. Pidd, a new death-domain-containing protein, is induced by p53 
and promotes apoptosis. Nature Genet. 2000;26:122-5. 
47. Tinel A, Tschopp J. The PIDDosome, a protein complex implicated in activation of caspase-2 
in response to genotoxic stress. Science. 2004;304:843-6. 
48. Deng CX, Zhang PM, Harper JW, Elledge SJ, Leder P. Mice lacking p21(CIP1/WAF1) undergo 
normal development, but are defective in G1 Checkpoint control. Cell. 1995;82:675-84. 
49. Eldeiry WS, Harper JW, Oconnor PM, Velculescu VE, Canman CE, Jackman J, et al. WAF1/CIP1 
is induced in p53-mediated G(1) arrest and apoptosis. Cancer Research. 1994;54:1169-74. 
50. Lindqvist A, de Bruijn M, Macurek L, Brás A, Mensinga A, Bruinsma W, et al. Wip1 confers G2 
checkpoint recovery competence by counteracting p53-dependent transcriptional repression. The 
EMBO Journal. 2009;28:3196-206. 
51. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, et al. COSMIC: 






Table 1 TP53 Wild-type and mutant/Null cell line pairs with different PPM1D genetic status. 
PPM1D status of SJSA-1 cells were obtained from sanger.ac.uk (51). TP53 mutant daughter 
cell lines of NGP and SJSA-1 cell lines were derived as described in Materials and Methods. 








Tumour of origin PPM1D genetic alteration (citation) 
SJSA-1 SN40R2 (E285K) Osteosarcoma Wild-type (51) 
HCT116+/+ HCT116-/-(Null) Colorectal carcinoma c.1344delT/Wt  (L450X) Gain-of-function (39)





Neuroblastoma Copy number gain (21) 






Figure 1 A) The effect on growth of a panel of p53 wild-type (Green) and Mutant/null 
(Maroon) cell line pairs with different PPM1D genetic status to 0.08-10µM GSK2830371 
exposure for  168hr, using sulforhodamine (SRB) growth inhibition assays. B) Basal 
expression of WIP1 and p53 in cell lines (SE-short film exposure, LE-long exposure). C) The 
sensitivity of a panel of p53 Wt (Green) and Mt/null (Maroon) cell line pairs with different 
PPM1D genetic status to 0.08-10µM Nutlin-3 and 0.008-1µM RG7388 in 168hr SRB growth 
inhibition assays in the presence and absence of the highest non-growth inhibitory dose of 
GSK2830371 (2.5µM). The U2OS cell line pair was treated with MDM2 inhibitors + 1.25µM 
GSK2830371. WIP1i: GSK2830371; FL-WIP1: Full length WIP1; S-WIP1: WIP1 shorter 
isoform; T-WIP1: Truncated WIP1 mutants, WIP1 L450X in HCT116 cells or WIP1 R458X in 
U2OS cells; S*-WIP1 the shortest band detected by the F-10 antibody. 
Figure 2 A) GSK2830371 (2.5µM) treatment of MCF-7 cells over 8 hours shows WIP1 
degradation over time, p53 stabilisation and Phospho-p53Ser 15 (pp53Ser15) accumulation. B) 
p53Ser15 phosphorylation in MCF-7 cells 30min post 2Gy ionising radiation in the presence or 
absence of 2.5µM. GSK2831371 inhibits WIP1 catalytic activity independent of WIP1 protein 
levels. C) 4 hours treatment with 2.5µM GSK2830371 results in degradation of full-length 
and truncated WIP1 in HCT116+/+ and U2OS cells. D) Lysates obtained from HCT116+/+ cells 
treated with 20µM proteasome inhibitor MG132 and 2.5µM GSK2830371 + 3.0µM Nutlin-3 
overnight underwent immunoprecipitation (IP) with anti-ubiquitin antibody (Ub-Ab) and the 
precipitates probed for WIP1 and p53 by western blot. Input samples are total lysates before 
IP for comparison western blots. An aliquot of MG132 treated lysate was precipitated with 
Rabbit IgG instead of Ub-Ab as a negative control. WIP1i: GSK2830371; Ub-Ab: anti-
ubiquitin antibody; WIP1 (Wt): Wild-type WIP1, WIP1 L450X: Truncated WIP1. 
Figure 3 A) Dose-dependent increased in caspase 3/7 activity of NGP cells after 24 hours 
treatment with Nutlin-3 (Nut-3 GI50 ≈ 3.0µM) alone or in combination with 2.5µM 
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GSK2830371. B) Increase in caspase 3/7 activity in NGP and SJSA-1 cells and their TP53 
mutant daughter cell lines 48 hours after treatment with Nutlin-3 + 2.5µM GSK2830371. C) 
Reduction in clonogenic efficiency of HCT116+/+ cells following exposure to 0.5 × GI50 
concentration of Nut-3 in the presence of 2.5µM GSK2830371 compared to either inhibitor 
alone over 10 days. D) Immunoblot of NGP cells showing Nut-3 dependent phosphorylation 
of p53 at Ser15 is markedly enhanced by GSK2830371 at 4 & 24hrs exposure and leads to 
increased caspase 3 cleavage at 48 hours. E) Time-course of NGP response to 3.0µM 
Nutlin-3 (≈GI50) ± 2.5µM GSK2830371 over 24 hours. WIP1i: GSK2830371; *: p ≤0.05; **: 
p≤0.005 
Figure 4 A & B) Volcano plots showing the significantly induced genes by RG7388 treatment 
of NGP cells for 4hrs in the presence or absence of 2.5µM GSK2830371 (RG7388 v DMSO 
and RG7388 + WIP1 (2.5µM) v DMSO). The results represent the mean of 4 independent 
biological repeats. y–axis: -Log10 of the p-value adjusted for false discovery rate using the  
Benjamini-Hochberg procedure; x-axis Log2 FC: Log2 fold-change in normalised mRNA 
expression. For a list of genes induced see Supplementary table S1A and Supplementary 
table S1B. Microarray data have been deposited in the NCBI GEO databank (Accession 
number: GSE75197). C) qRT-PCR validation of p53 target genes implicated in increased 
sensitivity to MDM2 inhibitors:TNFRSF10B, AEN , XPC and CDKN1A using the same RNA 
samples as used for the microarray analysis. D) Western blot for NGP cells showing 
changes in p53, pp53Ser15, MDM2, WIP1 and p21WAF1 protein expression in response to 
75nM RG7388 (GI50) + 2.5µM GSK2830371. Lysates were obtained from samples treated 
in parallel to the microarray experiment and represent the first 3 independent repeats. E) 
Western blot of HCT116+/+ cells 4 hours following treatment with the stated doses of Nutlin-3, 
GSK2830371 or their combination. F) Western blot showing changes in pp53Ser15, MDM2, 
and p21WAF1 detection 12 hours after ectopic expression of wild-type p53 (Wt), p53 mutants 
Ser15Ala (S15A) and Ser15Asp (S15D) in HCT116-/- cells. WIP1i: GSK2830371; *: p ≤0.05; 
**: p≤0.005; ***≤0.0005  
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Figure 5 A) Time-course of cell cycle distribution changes over 72Hrs of treatment using 
FACS analysis. B) % of Sub-G1 signals for NGP, SJSA-1, HCT116+/+ and HCT116-/- cells in 
response to the stated treatments at 72 hours. WIP1i: GSK2830371 
Figure 6 Proposed model for potentiation of cellular response to MDM2 inhibitors by the 
selective allosteric WIP1 inhibitor GSK2830371. After activation of p53 by MDM2 inhibitors, 
p53Ser15 is unmasked and therefore available as a substrate for the basal level activity of 
multiple kinases and phosphatases normally involved in post-translational modification of 
this residue in response to cellular stress. In normal homeostatic control, phosphorylation of 
p53Ser15 is kept in check by an equilibrium between the kinase and phosphatase activities. 
Inhibition of WIP1 by GSK2830371 tilts this balance in favour of the activating kinases which 
in turn increases p53 transcriptional activity and is enhanced in combination with MDM2 
inhibitors. Dashed lines indicate direct p53 transcriptional upregulation of the corresponding 









Supplementary figure S1 
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Supplementary Figure S4 
RG7388 (GI50) V DMSO 
Gene Symbol log2 (Fold-change) 
Adjusted 
p-value OR 
CDKN1A 2.07 0.002 3.95 
PHLDA3 1.58 0.002 3.94 
SESN1 1.12 0.018 2.57 
BTG2 0.84 0.002 3.80 
AEN 0.83 0.026 2.31 
TP53INP1 0.77 0.001 4.42 
RGMA 0.66 0.018 2.63 
C12orf5 0.59 0.016 2.85 
FAM212B 0.52 0.017 2.74 
RG7388 (GI50)+WIP1i (2.5µM) V DMSO 
Gene Symbol log2 (Fold-change) 
Adjusted 
p-value Odds ratio 
BTG2 1.31 0.0001 6.77 
TP53INP1 0.95 0.0001 6.76 
CDKN1A 2.67 0.0002 6.35 
PHLDA3 1.93 0.0002 6.15 
FAM212B 0.88 0.0002 6.09 
RGMA 0.96 0.0009 5.38 
C12orf5 0.77 0.0012 5.17 
SESN1 1.46 0.0019 4.84 
SESN2 0.58 0.0027 4.58 
ACTA2 0.71 0.0028 4.51 
XPC 0.66 0.0041 4.22 
ZNF79 0.43 0.0062 3.91 
AEN 0.85 0.0147 3.27 
NA 0.63 0.0151 3.21 
FAM212B 0.32 0.0178 3.04 
TNFRSF10B 0.52 0.0210 2.87 
PIDD1 0.37 0.0368 2.41 
TRIAP1 0.66 0.0389 2.33 
ARC 0.38 0.0420 2.23 
DDB2 0.29 0.0429 2.17 
MDM2 0.51 0.0434 2.10 
TOB1 0.53 0.0434 2.09 
BLOC1S2 0.31 0.0454 1.97 
GADD45A 0.74 0.0454 1.97 
ZMAT3 0.59 0.0454 1.96 
A B 
Supplementary table S1 
1. Supplementary figure S1
Supplementary figure S1: A) Volcano plot generated from the Wellcome Trust Sanger
Institute Cosmic database showing the most significant genetic mutational determinants
of response to MDM2 inhibition by Nutlin-3a. The plot shows the effect that genetic
events, in commonly mutated genes in cancer, have on the IC50 for Nutlin-3a across a
large panel of cell lines. The Y axis represents the p-value from multivariate ANOVA of
drug gene interaction on an inverted log10 scale. This shows TP53 genetic status to be
by far the strongest determinant of response to MDM2 antagonists (p=1.26e-54 ; Note this
is off the Y-axis scale). The size of the circle reflects the sample size. B) Box and
whiskers plot showing all the data associated with the TP53 node on the volcano plot
from Supplementary figure S1A illustrating the range of sensitivities to Nutlin-3a
among TP53 wild-type cell lines as determined by their IC50 values.
2. Supplementary figure S2
Supplementary figure S2: A) Western blot shows optimisation of anti-WIP1 antibody (F-
10) using siRNA mediated knockdown in MCF-7 cells. Following 24 and 48 hours of
siRNA mediated knockdown conditions, MCF-7 cells were treated with 10Gy IR, lysates
were collected after 4 hours and analysed by western blotting. All the bands shown were
knocked down in response to four different WIP1 targeting siRNA constructs (WIP1.1-4)
compared to the universal control siRNA (Cont. siRNA). WIP1 knockdown also resulted
in higher and persistent pp53Ser15 most notably in response to the WIP1.2 siRNA
construct. WIP1.1 Sense: GUGCCAUAGUAAUCUGCAU; WIP1.2 Sense:
GGUGUAGUCAUACCCUCAA; WIP1.3 Sense: GCCCUUCCUAUAAUAGUCA; WIP1.4
Sense: UUGGCCUUGUGCCUACUAA Universal control Sense:
GCGCGCUUUGUAGGAUUCG. B) Nutlin-3 and RG7388 SRB growth inhibition curves in
MCF-7 cells in the presence and absence of 2.5ÂµM GSK2830371. C) On the left side
two independent repeats of the western blot in Figure 2A showing degradation of WIP1
protein in MCF-7 cells over time following treatment with 2.5ÂµM GSK2830371. Full-
length WIP1 band optical density (OD) was normalised to actin OD over time.
3. Supplementary figure S3
Supplementary figure S3: A) The ratios pp53Ser15 band: total p53 band optical density
values (OD) in Figure 4F (Left) and 3D (Right) quantified using Imagej software. B)
Western blot showing changes in pp53Ser15, MDM2, and p21WAF1 expression 12 hours
after different concentrations of wild-type p53 (Wt), p53 mutants Ser15Ala (S15A) and
Ser15Asp (S15D) ectopic expression in HCT116-/- cells. C) The quantification of
p21WAF1 and MDM2 band OD values based on the last three lanes in Supplementary
figure S3B and Figure 4F. The OD values were normalised to the optical density value
calculated from the same area in the pcDNA3.1 track on each image.
4. Supplementary figure S4
Supplementary figure S4: A) Time-course of cell cycle distribution changes over 72 hours
of treatment using FACS analysis. NGP and SJSA-1 cells were treated either with DMSO
solvent control (Black), 2.5ÂµM GSK2830371 (Blue), (GI50) Nutlin-3 (Red) or Nutlin-3 +
GSK2830371 combination (Purple). HCT116+/+ cells were treated with 0.5 Ã— Nutlin-3
GI50 in single and in combination treatment. B) Representative cell cycle distribution
histograms for NGP and SJSA-1 cells indicating the increase in the proportion of Sub-
G1events in response to 72 hours of treatment with GSK2830371 (WIP1i), Nutlin-3 and
their combination.
5. Supplementary Table S1
Supplementary Table S1: A & B) List of genes with significantly increased mRNA levels
in NGP cells 4 hours following treatment with 75nm RG7388 (GI50 in NGP cells) +
2.5ÂµM GSK2830371. Genes were ordered based on p-value following Benjamini-
Hotchberg correction for multiple testing. OR: Odds ratio.
